The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years. With a 5-year survival rate of ~15%, the identification of new therapeutic targets for EAC is greatly important. We analyze the mutation spectra from whole-exome sequencing of 149 EAC tumor-normal pairs, 15 of which have also been subjected to whole-genome sequencing. We identify a mutational signature defined by a high prevalence of A>C transversions at AA dinucleotides. Statistical analysis of exome data identified 26 significantly mutated genes. Of these genes, five (TP53, CDKN2A, SMAD4, ARID1A and PIK3CA) have previously been implicated in EAC. The new significantly mutated genes include chromatin-modifying factors and candidate contributors SPG20, TLR4, ELMO1 and DOCK2. Functional analyses of EAC-derived mutations in ELMO1 identifies increased cellular invasion. Therefore, we suggest the potential activation of the RAC1 pathway as a contributor to EAC tumorigenesis.
A r t i c l e s In recent decades, the incidence of EAC has increased markedly in the United States and other Western countries 1, 2 . The increasing frequency and poor prognosis of this cancer represent a substantial health concern. EAC does not develop from the native esophageal epithelium but rather originates from intestinal metaplasia of the esophageal epithelium (Barrett's esophagus) that develops in response to chronic gastroesophageal reflux. Although the reason for the marked rise in these cancers is unknown, factors influencing the rising rates include gastroesophageal reflux disease (GERD), Barrett's esophagus and obesity 3 . There is great urgency to elucidate the genomic alterations underlying EAC to enhance understanding of these tumors, aid in early diagnosis and identify therapeutic targets.
Knowledge of the somatic mutations in EAC has been limited to studies in small collections of tumors. These studies have identified frequent mutations in TP53 (ref. 4 ) and CDKN2A 5 . Beyond these two genes, small, focused studies have noted sporadic mutations in APC 6 , BRAF 7 , CDH1 (ref. 8) , CTNNB1 (ref. 6) , EGFR 9,10 , KRAS 7 , PIK3CA 11 , PTEN 12 and SMAD4 (ref. 12) . Although comparative whole-exome sequencing has been reported for 11 EACs and esophageal squamous cell carcinomas, no clear contributors to EAC were identified at the gene level 13 .
Here, we describe the landscape and spectrum of genomic alterations in 149 fresh-frozen, surgically resected cases of EAC, including adenocarcinomas arising in the gastric-esophageal junction (GEJ), not treated with chemotherapy or radiation before surgery. All cases were subjected to whole-exome sequencing, with 16 tumor-normal pairs also analyzed by whole-genome sequencing. Examination of the somatic alterations in sample pairs identified a high frequency of mutations and rearrangements. Additionally, we identify a mutational signature defined by A>C transversions at AA dinucleotide sites (with the second adenine denoting the site of the mutation). Through systematic analysis of the mutated genes, we identify many genes not previously associated with this cancer. These include ELMO1 and DOCK2, upstream modulators of the RAC1 GTPase, and characterize the presence Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity High frequency of A>C transversions at AA sites in EAC Epithelial cancers often have variable mutation spectra pointing to particular mutagenic stimuli. Therefore, we analyzed the spectrum of mutations in EAC detected by whole-genome sequencing. Earlier exome sequencing of EACs noted A>C transversions to be more common in EAC compared to squamous esophageal carcinoma 13 . Evaluating the whole-genome sequencing data, we found that A>C base changes comprised an average of 34% of the total mutations (Supplementary Table 6 ). To comprehensively characterize the mutation spectra, we measured the frequencies of base mutations in different trinucleotide contexts and observed a preponderance of C>T transitions (39.2 mutations/Mb), as seen in most epithelial cancers. We further investigated the high frequency of A>C transversions (or equivalent T>G transversions on the complementary strand). These events showed preference (20.2 mutations/Mb) for the context of AA dinucleotides-that is, adenines flanked by a 5′ adenine and any 3′ nucleotide (Fig. 1a) . In total, 84% of A>C mutations were flanked by a 5′ adenine. Expanding on these findings, we found that A>C transversions at AA dinucleotides were most pronounced when the 3′ base was a guanine (49.3 mutations/Mb) and was lower when it was an adenine (8.0 mutations/Mb), cytosine (16.8 mutations/Mb) or thymidine (6.7 mutations/Mb) ( Supplementary Table 7 ). Validating these results, genotyping of randomly selected AA>AC mutations from intragenic regions showed a concordance rate of 100% (25/25) . The high frequency of AA>AC transversions seems to be unique to EAC, as equivalent events have not been identified in other cancer types 15, 16, [18] [19] [20] 24, 25 .
Overall, A>C transversions at AA sites accounted for 29% of the total mutations ( Fig. 1a) . Within individual tumors, these transversions at AA sites accounted for 5-48% of mutations ( Supplementary  Table 7 ), and the event number was correlated with the overall mutation frequency (R 2 = 0.92) ( Supplementary Fig. 2 ). When we excluded transversions at AA sites, the mutation frequency was 8.5 mutations/Mb, still higher than in most tumor types. Thus, AA>AC mutations do not fully explain the elevated mutation frequency in EAC relative to other cancers.
We next characterized the distribution of mutations in different genomic regions. Although A>C transversions remained notable at AA sites, the percentage of all mutations consisting of these transversions was significantly lower in exons (16%) than across the entire genome (AAG, P = 0.001; AAT, P = 0.0006; AAC, P = 0.0007; AAA, P = 0.0006; two-tailed Student's t test) ( Fig. 1a) . These results were consistent across the coding regions of all 16 cases evaluated by wholegenome sequencing ( Supplementary Tables 8 and 9 ). In contrast, the attenuation of C>T transitions at CG dinucleotides in coding regions (39.2 mutations/Mb versus 25.4 mutations/Mb) was smaller than that seen for transversions at AA dinucleotides.
The lower frequency of transversions at AA dinucleotides in coding areas relative to intergenic regions suggested that these mutations may be less likely to occur in transcribed regions or may be repaired effectively by transcription-coupled repair. To evaluate the potential impact of gene expression on mutation rates, we compared sample-specific frequencies of mutation at AA dinucleotides within gene boundaries at varying levels of gene expression in 14 whole-genome sequencing samples from which mRNA was available for microarray expression profiling. Higher expression was associated with lower global mutation frequency. Additionally, the impact of gene expression on attenuating mutation rates was threefold greater at AA sites than for mutations in other nucleotide contexts ( Fig. 1b and Supplementary  Table 10 ). This finding shows a strong effect of local gene expression on the development of transversions at AA sites in EAC.
Given the impact of transcription on these mutations, we analyzed transversions at AA sites for strand bias. The mutation rates for transversions at AA dinucleotides in introns and exons were calculated separately, according to whether the adenine base was on the transcribed or non-transcribed strand. The results indicated that AA>AC mutations were more common when the AA site was located on the nontranscribed strand (12.4 mutations/Mb versus 11.2 mutations/Mb; P = 0.0016, Student's t test, paired). When evaluating mutations at all base npg A r t i c l e s contexts other than AA dinucleotides, a strand bias was not detected (9.5 mutations/Mb versus 9.5 mutations/Mb; P = 0.9086, Student's t test, paired) ( Fig. 1c and Supplementary Table 11 ). These results suggest that transversions at AA sites may be more effectively recognized and repaired when the mutated adenine is located on the transcribed strand.
Mutations identified by exome sequencing
We next analyzed whole-exome sequencing data from 149 tumorgermline pairs ( Supplementary Table 12 ). A mean coverage depth of 83.3× was achieved in neoplastic DNA, and 85.9× coverage was achieved in the non-cancerous tissue. Of the exons, 89% were covered at 8× or greater depth for normal samples and at 14× or greater depth for tumor samples, a threshold at which MuTect is powered to detect a mutation with an allele fraction of above or equal to 0.3 (refs. 14,16,17,26) . We evaluated mutation calling by comparing candidate coding mutations identified by whole-exome sequencing to calls from whole-genome sequencing for the same tumor. Concordance of 85.1% (2,200/2,585) was observed for all events, and 90% concordance was seen for mutations present at greater than 0.1 allele fraction ( Supplementary Table 13 ).
Four tumors had markedly higher coding mutation frequencies than other cases (14.6-50.9 mutations/Mb). This pattern resembled that of CRC where a subset of tumors were hypermutated, which was largely attributable to microsatellite instability (MSI). Similarly, MSI-positive tumors have been reported to represent 7% of EACs 27 . The four cases with the highest mutation rates were found to be MSI positive, with the tumor with the highest mutation frequency having mutations in two mismatch repair genes, MSH6 and MSH3 ( Supplementary  Table 14 ). By contrast, none of the 24 EAC samples with the next highest mutation frequencies (greater than 5 mutations/Mb) scored positive for MSI. To avoid a potential confounding effect on statistical analysis, we omitted the MSI-positive cases from the final analysis, leaving 145 tumors.
A total of 17,383 mutations, consisting of 16,516 nonsilent mutations and 1,954 insertion-deletion and/or null mutations were detected in the 145-sample cohort for a median of 104 nonsilent coding mutations per tumor (Fig. 2) . The overall nonsilent median mutation frequency was 3.51 mutations/Mb (range of 0.97-10.8 mutations/Mb). We investigated whether the fraction of transversions at AA sites was associated with clinical variables, including age, disease stage, sex and tumor location. Notably, a trend was seen in which EACs developing within the tubular esophagus harbored a greater fraction of transversions at AA sites compared to tumors in the GEJ (P = 0.076, two-tailed Student's t test), a noteworthy result given the possibility that gastric refluxate in the lower esophagus serves as a mutagenic insult ( Fig. 2 and Supplementary Fig. 3 ). No other significant associations were identified.
Genes significantly mutated in esophageal adenocarcinoma
We observed mutations in 8,331 genes, of which 3,639 were mutated in 2 or more samples ( Supplementary Table 15 ). Of these genes, 199 were mutated in 5% or more of the tumors, including 33 genes mutated in over 10% of cases. To identify genes showing evidence of positive selection for mutation, we used the mutation significance algorithm MutSig [14] [15] [16] 26 . This tool compares the mutation occurrence in each gene to that which would be expected by chance given a background mutation frequency model that factors in the mutation spectra, presence of silent mutations, mutation frequencies and regional mutation frequencies along the genome 19 . We found 26 genes to be significantly mutated (false discovery rate (FDR) q < 0.1), with 2 known tumor suppressors in EAC, TP53 and CDKN2A, being the most significant ( Fig. 2) . With the exception of ARID1A, PIK3CA . Inset pie charts indicates the distribution of all mutations for a given middle mutated base across the territory being evaluated. A>C transversions at AA dinucleotides are denoted by an asterisk. (b) Gene expression was detected with Affymetrix U133 Plus 2 arrays on a persample basis for 14 whole-genome sequenced samples. Mutation frequencies within introns and exons were calculated as the number of mutations detected per million at-risk bases sequenced for a mutation category. Mutation frequencies, as they vary by gene expression (with genes binned into quartiles on the basis of gene expression), are plotted separately for all mutations and for transversions at AA sites. (c) The mean frequency of mutations (number of mutations per million bases at risk for mutation) within intronic and exonic regions are plotted with frequencies separated on the basis of whether the base at risk is present on the transcribed or non-transcribed strand. For the transversions at AA sites, the mutation frequency is calculated separately for the case of at-risk adenine bases when present on the coding or noncoding strands compared to similar analysis for all other base contexts. P values were calculated by Student's t test. All error bars, s.d.
A r t i c l e s and SMAD4, no other significantly mutated gene had previously been implicated in EAC, although several had been implicated in other cancers.
Notably, two significantly mutated genes, ELMO1 and DOCK2, encode dimerization partners and intracellular mediators of the Rho family GTPase, RAC1 (refs. 28, 29) . Because aberrant RAC1 activation has been implicated in malignant transformation in other cancer types, mainly by enhancing cellular motility [30] [31] [32] [33] [34] , recurrent mutations in these genes may be functionally important. Although no RAC1 or RAC2 mutations were identified, ELMO1 or DOCK2 was mutated in 25 EAC samples (17%), with 2 samples having mutations in both genes and 2 samples having 2 independent mutations in DOCK2 ( Fig. 3 and Supplementary Table 15 ). Notably, a single amino acid, Lys312 of ELMO1, was affected by mutation in three tumors, which suggests a gain-of-function phenotype. DOCK2 is a guanine nucleotide exchange factor (GEF) that activates RAC1 directly through GTP loading 28, 35 . To fully activate RAC1, DOCK2 and ELMO1 interact to relieve mutual autoinhibition 29 . In cancer models, ELMO1 and other DOCK family members have been associated with enhanced migration and invasion 36, 37 . Mutations were also present in other RAC1 GEFs (TRIO, TIAM1, VAV2 and ECT2) ( Supplementary Fig. 4 ). Furthermore, we previously observed focal copy number gain of the 11q13 locus containing the serine-threonine kinase PAK1, which encodes a principal downstream effector of RAC1 that has been shown to be oncogenic in breast cancer 23, 38 . The aberrant activation of genes related to RAC1 suggests that the motility pathway might be important in EAC.
To examine the relevance of ELMO1 mutations, wild-type and mutant ELMO1 constructs were generated and introduced into NIH/3T3 cells. On the basis of studies in glioblastoma showing a correlative increase in cellular invasion with the overexpression of wild-type ELMO1 (ref. 37) , we hypothesized that ELMO1 mutations would enhance cell invasion. Compared to green fluorescent protein (GFP) control, wild-type ELMO1 increased invasion by sevenfold (P = 0.0040, Student's t test, unpaired) ( Fig. 3c ). ELMO1 alterations (p.Phe59Leu, p.Lys312Glu, p.Lys312Thr, p.Lys349Arg and p.Thr421Asn) resulted in further significant increases (two-to sevenfold) in invasion compared to wild-type ELMO1 (Fig. 3c) . These results suggest that ELMO1 mutations can increase invasiveness and potentially contribute to tumorigenesis in EAC.
Additional significantly mutated genes included members of the SWI/SNF family of chromatin-remodeling factors: ARID1A, SMARCA4 and ARID2. Together, these genes were mutated in 20% of tumors. The enzymatic subunit of the chromatin-remodeling npg A r t i c l e s complex, SMARCA4, has been established as a putative tumor suppressor 14, 39 . Likewise, ARID1A and ARID2 have been implicated as tumor suppressors in cancers including gastric cancer [40] [41] [42] [43] . Notably, a candidate protein fusion identified by whole-genome sequencing also targeted SMARCA4. The predicted fusion between exon 11 of SMARCA4 and exon 14 of DNM2 might point to an alteration that results in a loss-of-function phenotype ( Supplementary Table 5 Figs. 4 and 5) .
Another noteworthy gene was SPG20, which was mutated in 7% of EACs, with five of the mutations generated by transversions at AA dinucleotides (Supplementary Fig. 6) . Spartin, the gene product of SPG20, was reportedly mutated in Troyer syndrome 45 , a genetic disorder characterized by progressive muscle stiffness and limb paralysis. The functions of Spartin include the endosomal trafficking of growth factor receptors, inhibition of bone morphogenetic protein signaling and ubiquitin targeting 46 . More recently, SPG20 hypermethylation has been linked to colon cancer progression 47 .
TLR4 was mutated in 6% of EACs. Germline polymorphisms in TLR4 correlate with risk of Helicobacter pylori-mediated gastric carcinoma 48 . In a lung cancer model, TLR4 inactivation through mutation contributes to greater inflammation and tumorigenesis 49 . TLR4 activates the innate immune response to pathogen exposure through heterodimerization with MD-2 (ref. 50) . Notably, the mutations in TLR4 affect residues between amino acids Asp379 and Phe487, a region critical for MD-2 interaction 51 . One mutation affects Glu439, a site essential for the hydrogen bonding of TLR4 with MD-2 ( Supplementary Fig. 6 ). These mutations suggest disruption of the TLR4-MD-2 complex as a potential driver of tumor progression in EAC.
We also identified other significantly mutated candidate genes, including the protein kinase A-anchoring factor AKAP6 (mutated in 8% of samples), the E3 ubiquitin ligase HECW1 (8%) and AJAP1 (6%), which mediates signaling at adherens junctions and increases invasiveness in cancer cell lines 52 . NUAK1 (also known as ARK5) was mutated in 3% of cases, which is notable given that Figure 4 Somatic mutations in frequently altered pathways in cancer, putative therapeutic targets and treatment biomarkers. Potential therapeutic targets or treatment biomarkers are listed by sample. Each column denotes an individual tumor, and each row represents a gene. Mutations are colored by the type of mutation event, and genes with amplification of greater than four copies relative to diploid baseline are marked by red outlines.
A r t i c l e s
The lysine acetyltransferase KAT6A (also known as MYST3), recurrently targeted by translocation in leukemia 54 , was also mutated in seven specimens (5%) (Supplementary Fig. 6 ).
Additional candidate genes
Beyond the genes mutated at a statistically significant frequency, we queried the data for mutations of biological relevance given their recurrence in other cancers. We identified mutations in EAC that had been seen 2 or more times across all cancers in the Catalogue of Somatic Mutations in Cancer (COSMIC) database 55 : we found 22 such genes ( Supplementary Table 16 ). Additionally, ten genes were significantly mutated (FDR q < 0.1) in limited analysis of COSMIC gene territory, including KRAS, CTNNB1 and ERBB2 (Supplementary Table 17 ). These results indicate that genes not reaching statistical significance in the cohort may harbor mutations of biological relevance in individual tumors.
Mutations targeting therapeutically relevant genes
We queried the data for mutations in genes encoding the therapeutic targets of inhibitors approved for clinical use or in preclinical development 56 . Mutations in actionable genes were discovered in 23% of tumors, with PIK3CA being the most frequently mutated (Fig. 4) .
When also evaluating the amplification status of genes, 48% of tumors in this cohort had a genomic alteration in a gene with a targeted agent. The high frequency of focally amplified therapeutic targets 23 exceeded that of mutation in these same genes in EAC. Therefore, determining how to effectively treat tumors with amplified targets, especially receptor tyrosine kinases (RTKs), should be considered a priority.
Somatic alterations in signal transduction pathways
To explore the functional impact of the mutations, we performed unbiased Gene Ontology (GO) term enrichment in the overall ranked MutSig list using the 8,356 genes with at least 1 nonsilent mutation 57, 58 . GO processes related to cell adhesion and chemotaxis ranked as enriched near the top of the list ( Supplementary Table 18 ). These findings support the hypothesis that enhanced cellular motility and invasiveness has an important role in EAC disease progression. We also studied how cancer-associated pathways were disrupted by mutation in EAC. Cell cycle control was altered by point mutation in 14% of EACs, with most of the mutations occurring in CDKN2A Figure 5 Genetic alterations identified by whole-exome sequencing across 145 EACs affecting the Wnt/β-catenin, RTK-RAS-PI3K, TGF-β/SMAD4, chromatin-remodeling enzyme, G1 to S progression and p53 pathways. Percentages represent the number of mutations in a given gene across the cohort. Genes that are predicted to have gain or loss of function are depicted in red and blue, respectively, with color intensity based on the mutation frequency of a given gene. Frequencies of alteration by mutation or copy number variation are shown. Genes subject to significant focal gain or loss in EAC 23 have copy number frequencies marked in bold.
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A r t i c l e s ( Fig. 5 and Supplementary Fig. 4) . This process was also frequently affected by amplifications at the CCND1, CCNE1 and CDK6 loci 23 .
Although activation of β-catenin signaling is ubiquitous in CRC, mutations in this pathway were found in only 9% of EACs, with two tumors having APC mutations that coincided with mutation in either CDH1 or AXIN1 ( Fig. 5 and Supplementary Fig. 4) . Moreover, a potential AXIN1 fusion was identified by whole-genome sequencing in sample ESO-1060 spanning exon 5 of AXIN1 and exon 2 of GALNT7, which might alter normal gene function (Supplementary Table 5 ). As in other cancer types, the TGF-β-SMAD signaling pathway was mutated in 18% of EAC tumors. The most recurrently altered gene in this pathway was SMAD4, which was mutated in ten samples and was also subject to frequent copy number loss ( Fig. 5 and  Supplementary Fig. 4) .
We evaluated the frequency and manner of somatic alterations in mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling, two common pathways required for the proliferation and survival of cancer cells. Unlike in other epithelial tumor types where MAPK pathway mutations are common, no BRAF mutations were observed in EAC, and NF1 and KRAS mutations were seen in only three (2%) and five (3%) tumors, respectively. Three of the five KRAS mutations altered Gly12; however, one EAC harbored a KRAS c.351A>C (p.Lys117Asn) event, a mutation caused by a transversion at an AA dinucleotide that was previously observed in CRC 59 . The PI3K pathway was the most frequently altered oncogenic pathway affected by mutation (13%). PIK3CA was mutated in seven tumors, and PIK3R1 and PTEN were mutated in five and four tumors, respectively ( Fig. 5b and Supplementary Fig. 4) .
We explored mutations in the ErbB family of RTKs, which are important therapeutic targets in many cancer types. Although three samples harbored EGFR mutations, these alterations were not previously annotated in other tumors. Moreover, two of these alterations, p.Ser447Tyr and p.Ser1153Ile, were predicted by PolyPhen-2 score 60 to not be deleterious to normal function and were thus of questionable biological relevance. By contrast, ERBB2 mutations were present in five tumors. Three mutations affected the kinase domain, including two c.351A>C (p.Asp769Tyr) mutations and one c.2327G>T (p.Gly776Val) mutation. These alterations have been observed previously in other cancers [61] [62] [63] .
DISCUSSION
Here, through mutation analysis, we provide insight into somatically altered genes and signaling pathways, as well as confirm a high rate of A>C transversions in EAC 13 . We further establish that the rates of these mutations are highest in noncoding regions and, within coding areas, are over-represented in less expressed genes. Additionally, we demonstrate the context specificity of these mutations, showing that A>C transversions are most common when the mutated adenine follows a 5′ flanking adenine (AA), especially at AAG trinucleotides.
This mutational spectrum seems to be unique to EAC, suggesting that these mutations are attributable to gastroesophageal reflux, where the gastric and duodenal contents travel into the lower esophagus, creating an environment of inflammation 22 . Previous studies have linked particular substances such as bile acids, nitrosamines and reactive oxygen species to the development of metaplasia and carcinomas 64 , but the precise mutagen(s) remain poorly understood. Experiments in Escherichia coli exploring the mutagenic potential of an oxidatively damaged DNA precursor, 8-hydroxydeoxyguanosine triphosphate, showed that it preferentially induces A>C transversions 65 . These data suggest that A>C transversions in EAC might arise from the oxidative damage induced by GERD; however, experimental evidence is necessary to identify a culprit stimulus. The identification of this mutational signature enables future studies to define specific carcinogen(s) that contribute to EAC that potentially aid in the explanation of the rising incidence of this cancer.
Statistical analysis also enabled a comprehensive assessment of mutated genes in EAC and identified mutations in cancer-related genes such as TP53, CDKN2A, SMAD4 and PIK3CA. It was notable that most well-annotated cancer genes were not affected by transversions at AA sites. In many cases, it is impossible to generate hotspot mutations, such as those affecting KRAS Gly12 or PIK3CA Glu545, with a transversion at an AA dinucleotide. Additionally, given the base composition of stop codons, it is difficult to generate nonsense events from transversions at AA sites and impossible to create a stop mutation from an A>C transversion when it occurs in an AAG trinucleotide context, the most common context for mutations at AA sites in our data set. Of the 2,570 coding mutations caused by these events, none is a predicted nonsense mutation. Moreover, the data suggest that transversions at AA sites accumulate in genes with lower expression, thus reducing their prevalence in the genes contributing to oncogenesis. Despite these caveats, it is likely that the mutations caused by transversions at AA dinucleotides do affect genes relevant for these tumors. For example, a known transforming mutation in KRAS (c.351A>C; p.Lys117Asn) is created by a transversion at an AA dinucleotide.
Consistent with previous reports [39] [40] [41] [42] [43] [44] , loss-of-function mutations in chromatin-remodeling enzymes are common in EAC. Previous gene studies have also suggested frequent activation of the MAPK, PI3K and β-catenin pathways. The data presented here verify the presence of frequent mutations in the PI3K cascade but argue against wide-reaching mutations in these pathways, thus drawing contrasts between EAC and CRC, where β-catenin activation and missense mutations of KRAS and BRAF are highly prevalent 66 .
For the first time, we detected EAC-relevant mutations in regulators of invasion and motility, including significantly recurrent mutations in DOCK2 and ELMO1. These mutations may increase tumor fitness through alteration of cytoskeletal structure, increase in invasive properties or mitogenesis. We show that ELMO1 mutations augment cellular invasiveness, thus suggesting one mechanism by which these events contribute to tumorigenesis. Given that EAC is a highly invasive tumor that is prone to early metastasis, alterations in the RAC1 pathway may contribute to this phenotype.
Although we identified potentially actionable genomic alterations in 48% of samples, the trastuzumab antibody to ERBB2 (also known as HER2) is the only targeted agent used in the treatment of GEJ adenocarcinomas, which include EAC adenocarcinomas, with its use guided by the overexpression and genomic amplification of ERBB2 (ref. 67) . Currently, ERBB2 mutation assessment is not performed for EAC, despite ERBB2 being altered by both amplification and mutation in 3% of samples. The current data point to a potential use of mutation as an additional biomarker to guide the use of ERBB2-targeting agents.
Limited knowledge of the genomic aberrations underlying EAC has hindered the development of new therapies. Numerous candidates, not previously implicated in this disease, have emerged from the current analysis. Functional study of these genes will be required to validate and understand their roles in tumorigenesis and to identify the etiology of the unique spectrum of observed transversions at AA dinucleotides. These data provide an enhanced road map for the study of EAC and the much-needed development of new therapies for this deadly cancer. 
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METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. Binary sequence alignment/map (BAM) files were deposited in the database of Genotypes and Phenotypes (dbGaP) under accession phs000598.v1.p1. Raw mRNA expression data for 14 EAC samples have been deposited at the Gene Expression Omnibus (GEO) under accession GSE42363.
ONLINE METHODS
DNA extraction and sample collection. All samples were obtained under institutional review board (IRB) approval and with documented informed consent. All samples were fresh-frozen primary resections from individuals with EAC not treated with previous chemotherapy or radiation. Slides stained with hematoxylin and eosin were examined by a board-certified pathologist to select cases with estimated carcinoma content of >70%. DNA was extracted using salt precipitation or phenol-chloroform extraction. DNA was quantified using PicoGreen dsDNA Quantitation Reagent (Invitrogen).
Whole-exome sequencing. Whole-exome capture libraries were constructed from 100 ng of tumor and normal DNA after shearing, end repair, phosphorylation and ligation to barcoded sequencing adaptors 68 . Ligated DNA was size selected for lengths between 200 and 350 bp and subjected to exonic hybrid capture using SureSelect v2 Exome bait (Agilent Technologies). Samples were multiplexed and sequenced on multiple Illumina HiSeq flow cells to average target exome coverage of 83.3× in neoplastic DNA and 85.9× in non-cancerous tissue.
Whole-genome sequencing. Samples were chosen for whole-genome sequencing on the basis of purity and ploidy estimates from ABSOLUTE 69 . Wholegenome sequencing library construction was carried out with 500 ng of native DNA from primary tumor and germline samples for each individual. DNA was sheared to a range of 101-700 bp using the Covaris E210 Instrument and then phosphorylated and adenylated according to the Illumina protocol. Adaptorligated purification was performed by preparatory gel electrophoresis (4% agarose at 85 V for 3 h), and size was selected by excision of two bands (at 500-520 bp and 520-540 bp), yielding two libraries per sample with average sizes of 380 and 400 bp, respectively 15, 16, 21 . Qiagen Min-Elute column-based cleanup was performed after each step. For a subset of samples, gel electrophoresis and extraction were performed using the automated Pippin Prep system (Sage Science). Libraries were then sequenced with the Illumina Genome Analyzer IIx or the Illumina HiSeq sequencer with 101-bp reads, achieving an average of ~30× coverage depth.
Identification of rearrangements.
The dRanger algorithm was used to detect genomic rearrangements by identifying instances where the two read pairs mapped to distinct regions of the genome or mapped in a manner that suggested another structural event such as an inversion. Candidate somatic rearrangements were queried in both the matched normal genome and a panel of non-tumor genomes to remove germline events. The final scorings of these somatic reads were then calculated by multiplying the number of supporting read pairs by the estimated quality of the candidate rearrangement (0 to 1). This metric is generated by taking into account the ability to align of the two regions joined by the putative rearrangement and the chance of detecting such a read pair given the library fragment size distribution. Events with scores of ≥4 (observed in at least 4 read pairs) were included in this analysis.
Validation of selected mutations by mass spectrometry genotyping.
A total of 45 intergenic AA>AC mutations were selected for validation in tumor and germline sample using mass spectrometry genotyping (Sequenom). Mutations were randomly selected across six samples, and sites chosen all had estimated mutation allelic fractions exceeding 30%, thus enabling mutation detection 20, 26, 70 . Of those assays performed, 25 yielded interpretable data, with others failing owing to lack of PCR amplification or probe hybridization in the tumor and/or germline samples.
Sequencing data processing and quality control. The processing and analysis of exome and whole-genome sequencing data were performed using Broad Institute pipelines 15, 16, 26, 70 . A BAM file aligned to the hg19 human genome build was generated from Illumina sequencing reads for each tumor and normal sample by the Picard pipeline. The Firehose pipeline was used to manage input and output files and submit analyses for execution in GenePattern 71 .
Quality control modules in Firehose were used to compare the genotypes derived from Affymetrix arrays and sequencing data to ensure concordance. Genotypes from SNP arrays were also used to monitor for low levels of crosscontamination between samples from different individuals in sequencing data using the ContEst algorithm 72 . One tumor-normal pair (ESO-774) analyzed by whole-genome sequencing was not included in the exome analysis, as the exome sequencing from that case failed quality control metrics.
Mutation calling. The MuTect algorithm was used to identify somatic mutations in targeted exons and whole-genome data 14, 16, 17, 26 . MuTect identifies candidate somatic mutations by Bayesian statistical analysis of bases and their qualities in the tumor and normal BAM files at a given genomic locus. We required a minimum of 14 reads covering a site in the tumor and 8 in the normal sample to declare that a site was adequately covered for mutation calling. We determined the lowest allelic fraction at which somatic mutations could be detected on a per-sample basis, using estimates of cross-contamination from the ContEst pipeline 72 . Small somatic insertions and deletions were detected using the Indelocator algorithm, after local realignment of tumor and normal sequences 14 . All somatic mutations detected by whole-exome sequencing were analyzed for potential false positive calls by performing a comparison to mutation calls from a panel of 2,500 germline DNA samples. Mutations found in 2% of the germline samples or 2% of sequencing reads were removed from analysis. MutSig significant mutations, except for all TP53 mutants, were reviewed manually in the respective BAM files using the Integrative Genomics Viewer.
Mutation annotation. Somatic point, insertion and deletion mutations were annotated using information from publicly available databases, including the UCSC Genome Browser's UCSC Genes track 73 Mutation significance analysis. For the purpose of discovering recurrently mutated genes, we used the MutSig algorithm, as described 19 . In short, this method builds a background model of mutational processes, which takes into account the genome-wide variability in mutation rates. We achieved this by considering different covariates that have been shown to affect mutation rate: GC content (measured on 100-kb windows), local relative replication time 78, 79 , open versus closed chromatin status as determined by HiC (fine-scale mapping of the three-dimensional DNA contacts in the nucleus 80 ), gene expression 16 and, finally, local gene density measured in a 1-Mb window. For each gene, we defined a set of nearest neighbors according to these covariates and estimated the background mutation rate from noncoding (in flanking sequences and introns) and silent mutations of these neighbors. We then assigned a score based on the ratio between the nonsilent coding mutation rate of the gene and the noncoding and silent mutation rate of the given gene and its neighbors. Furthermore, we performed an independent significance analysis that was restricted to events that had been previously reported in the COSMIC database. MSI testing. MSI analysis was performed using ten microsatellite markers (D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67 and D18S487) as described previously 23 . Processing of Affymetrix expression arrays. Raw data were processed using the gene chip robust multiarray averaging 81 (RMA) approach to provide normalized expression data for each probe set on the arrays.
Cell lines and culture conditions. NIH/3T3 and 293 cells were obtained from the American Type Culture Collection. All cells were maintained in DMEM supplemented with 10% FBS at 37 °C in 5% CO 2 .
ELMO1 site-directed mutagenesis. Full-length ELMO1 cDNA was obtained from Open Biosystems-Thermo Scientific and cloned into the EcoRI site of pBabe(puro). Mutants were generated by site-directed mutagenesis using the QuikChange II Site-Directed Mutagenesis kit (Agilent Technologies) according to the manufacturer's instructions. All mutations were verified by sequencing. 
